No definition available.
Acquired pure red cell aplasia [erythroblastopenia]
D3_ACQPUREREDCLLAPLASIA
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
557745 |
1. Apply sex-specific ruleNone |
557745 |
2. Check conditionsNone |
557745 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
171 |
4. Check minimum number of eventsNone |
171 |
5. Include endpointsNone |
171 |
6. Filter based on genotype QC (FinnGen only) |
155 |
Control definitions (FinnGen only)
- Control exclude
- D3_APLASTICANDOTHANAEMIA
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- D60-D64
- Name in latin
- Erythroblastopenia [pura] acquisita
Similar endpoints
↥List of similar endpoints to
Acquired pure red cell aplasia [erythroblastopenia]
based on the number of shared cases.
Similar with more cases:
- Aplastic and other anaemias
- Anaemias
- Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism
- Any prescribed medicine buy
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1585 | 812 | 763 |
| Only index persons | 1228 | 642 | 586 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.02 | 0.02 | 0.02 |
| Only index persons | 0.02 | 0.02 | 0.02 |
| Median age at first event (years) | |||
| Whole population | 50.27 | 49.87 | 50.40 |
| Only index persons | 51.23 | 50.58 | 51.94 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 155 | 77 | 78 |
| Unadjusted period prevalence (%) | 0.03 | 0.03 | 0.04 |
| Median age at first event (years) | 61.84 | 56.48 | 67.13 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 160
- Matched controls
- 1600
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D60.9
ICD-10 Finland
Acquired pure red cell aplasia, unspecified
+∞
101.0
86
*
D64.9
ICD-10 Finland
Anaemia, unspecified
37.2
98.5
69
32
XW000
NOMESCO Finland
Bone marrow biopsy
15.8
34.2
32
25
D60.0
ICD-10 Finland
Chronic acquired pure red cell aplasia
+∞
33.5
31
*
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
5.3
24.8
84
276
D60.1
ICD-10 Finland
Transient acquired pure red cell aplasia
+∞
22.4
21
*
D50.9
ICD-10 Finland
Iron deficiency anaemia, unspecified
8.4
22.1
32
46
122
Kela drug reimbursment
Aplastic anaemia
+∞
20.2
19
*
WW500
NOMESCO Finland
Blood transfusion
8.9
17.9
24
31
D60.8
ICD-10 Finland
Other acquired pure red cell aplasias
+∞
15.9
15
*
L04AD01
ATC
ciclosporin; systemic
30.5
14.7
19
7
D61.9
ICD-10 Finland
Aplastic anaemia, unspecified
+∞
13.7
13
*
UJF32
NOMESCO Finland
Coloscopy
3.5
12.3
61
242
UJF92
NOMESCO Finland
Capsular endoscopy
64.4
10.8
12
*
D12.6
ICD-10 Finland
Benign neoplasm: Colon, unspecified
6.0
10.7
20
37
J01MA12
ATC
levofloxacin; systemic
3.4
10.5
50
191
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
3.8
10.4
38
122
D50.0
ICD-10 Finland
Iron deficiency anaemia secondary to blood loss (chronic)
11.8
10.1
18
17
B03BA03
ATC
hydroxocobalamin; parenteral
5.4
9.6
20
41
28404
ICD-8 Finland
Aplastic anaemia, Erythroblastopenia acquisita
+∞
9.5
9
*
B82
ICPC
Anaemia other/unspecified
12.5
9.3
16
14
Z2446
NOMESCO Finland
Social worker
4.6
9.1
23
56
N18.9
ICD-10 Finland
Chronic kidney disease, unspecified
4.5
8.7
23
58
TPH04
NOMESCO Finland
Cathetrisation of vein
2.9
8.1
49
212
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.6
8.1
93
556
A49.9
ICD-10 Finland
Bacterial infection, unspecified
3.4
7.5
31
107
D46.9
ICD-10 Finland
Myelodysplastic syndrome, unspecified
83.8
7.5
8
*
Z2221
NOMESCO Finland
Medical doctor
2.6
7.3
56
273
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
2.5
7.2
71
390
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
2.9
7.0
39
160
A41.0
ICD-10 Finland
Sepsis due to Staphylococcus aureus
14.6
7.0
11
8
138
Kela drug reimbursment
Severe anaemia associated with chronic renal failure
11.7
6.9
12
11
Y83
ICD-10 Finland
Surgical operation and other surgical procedures as the cause of abnormal reaction of the patient, or of later complication, without mention of misadventure at the time of the procedure
3.8
6.8
22
64
TPH15
NOMESCO Finland
Insertion of central venous catheter through external or internal jugular vein
4.4
6.8
18
45
ZX120
NOMESCO Finland
Intravenous
3.4
6.8
27
91
D64.8
ICD-10 Finland
Other specified anaemias
13.0
6.7
11
9
ZXD05
NOMESCO Finland
Urgent procedure
2.4
6.6
60
315
Z3231
NOMESCO Finland
Registered nurse
2.5
6.5
58
301
L04AX01
ATC
azathioprine; systemic
8.7
6.5
13
16
TK800
NOMESCO Finland
Hemodialysis
11.7
6.4
11
10
D51.9
ICD-10 Finland
Vitamin B12deficiency anaemia, unspecified
18.9
6.3
9
5
D69.0
ICD-10 Finland
Allergic purpura
27.9
6.3
8
*
NEA10
NOMESCO Finland
Exploration of soft tissue of pelvis, percutaneous
+∞
6.3
6
*
117
Kela drug reimbursment
Leukaemia and other malignant diseases of the blood and bone marrow, and malignant diseases of the lymphatic tissue
4.4
6.3
16
39
A28
ICPC
Limited function/disability NOS
2.6
6.2
45
211
J01MA02
ATC
ciprofloxacin; systemic
2.3
6.1
75
445
GD1PA
NOMESCO Finland
X-ray examination of the lungs in one projection
3.1
6.1
28
103
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
57
49
17.52
59.24
2.9
2.0
1.31
1.42
g/l
0.31
49
44
37
29
16.30
39.70
1.7
1.9
—
—
—
0
0
87
337
4.47
19.84
3.5
2.1
3.02
2.77
mg/l
0.32
79
282
50
186
3.46
11.05
12.8
5.7
1.09
1.09
mmol/l
0.02
45
169
21
41
5.74
10.64
3.3
2.6
1.91
2.90
ratio
0.26
16
19
55
228
3.15
10.08
2.3
1.7
1121.70
1199.39
nmol/l
0.26
40
171
54
224
3.13
9.86
2.8
1.9
—
—
—
0
0
95
556
2.74
8.88
11.1
4.8
34.19
35.65
g/l
1.67
88
520
43
166
3.17
8.77
6.7
3.3
8.22
6.39
umol/l
0.34
37
147
18
23
8.67
8.64
1.2
1.3
—
—
—
0
0
115
750
2.90
8.57
21.5
9.0
3.83
4.14
e9/l
0.91
104
643
18
24
8.30
8.43
1.2
1.4
—
—
—
0
0
18
24
8.30
8.43
1.3
1.4
214.38
363.73
u/ml
—
8
11
99
603
2.68
8.37
9.7
2.7
—
—
estimate
—
0
0
39
146
3.21
8.34
10.3
7.3
0.01
0.70
mmol/l
0.41
32
127
64
321
2.66
7.96
6.5
3.0
352.16
346.59
umol/l
0.13
55
269
28
95
3.36
6.95
10.1
8.6
24.02
24.34
mmol/l
0.17
28
95
40
168
2.84
6.91
2.7
1.8
—
—
—
0
0
70
389
2.42
6.81
2.4
1.7
21.97
20.71
nmol/l
0.27
59
309
91
568
2.40
6.80
3.7
2.1
89.10
96.45
pmol/l
0.97
57
285
23
70
3.67
6.71
2.3
1.8
—
—
—
0
0
37
153
2.84
6.55
2.9
2.0
—
—
—
0
0
101
673
2.36
6.32
16.8
6.8
1.20
1.21
mmol/l
1.11
90
580
6
0
+∞
6.29
2.2
0.0
—
—
—
0
0
9
6
15.78
5.97
1.1
3.2
—
—
—
0
0
9
6
15.78
5.97
1.1
3.2
—
—
—
0
0
13
21
6.63
5.51
1.3
1.3
133.83
166.49
au/ml
—
6
9
26
97
3.01
5.49
1.8
1.4
—
—
—
0
0
58
326
2.22
5.24
5.1
2.3
—
—
—
0
0
8
10
8.35
4.11
2.3
1.8
8.19
3.76
mg/l
—
8
10
8
10
8.35
4.11
1.4
1.4
—
—
—
0
0
7
7
10.38
4.05
1.1
1.0
—
—
—
0
0
9
15
6.29
3.87
1.4
1.5
—
—
—
0
0
15
50
3.21
3.80
5.1
2.5
—
—
—
0
0
6
5
12.39
3.79
1.3
1.0
—
—
—
0
0
22
92
2.61
3.76
4.4
6.0
2.95
1.44
mmol/l
0.85
15
69
11
25
4.64
3.70
2.4
1.5
—
—
—
0
0
10
21
5.00
3.62
16.8
1.5
34.10
32.90
pg
—
10
21
46
269
2.00
3.58
6.0
3.7
49.15
196.06
ng/l
1.63
39
213
73
502
1.84
3.46
5.2
3.4
—
—
—
0
0
22
97
2.47
3.38
2.9
3.5
271.09
216.55
ng/l
0.17
22
86
11
28
4.14
3.36
1.5
1.5
—
—
—
0
0
11
28
4.14
3.36
1.5
1.5
—
—
—
0
0
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
13
39
3.54
3.31
1.5
2.3
0.46
0.39
iu/ml
—
5
23
6
7
8.84
3.29
1.8
2.9
—
—
—
0
0
7
11
6.59
3.22
2.3
2.5
0.49
0.45
e9/l
—
7
11
19
80
2.56
3.20
1.8
1.4
—
—
—
0
0
9
20
4.70
3.16
2.7
1.5
—
—
—
0
0
13
45
3.06
3.10
1.2
1.2
—
—
—
0
0
13
45
3.06
3.10
2.4
1.5
—
—
—
0
0
11
32
3.61
2.96
2.0
1.5
—
—
—
0
0
12
38
3.33
2.92
2.3
1.5
—
—
—
0
0
11
33
3.50
2.87
2.3
1.6
—
—
—
0
0
116
948
1.81
2.84
4.9
4.2
15.02
14.92
pmol/l
0.15
110
840
13
48
2.86
2.79
2.6
1.7
—
—
—
0
0
5
6
8.55
2.77
2.2
1.3
0.55
0.60
mmol/l
—
5
6
65
455
1.72
2.76
4.7
3.3
2.34
2.36
mmol/l
0.55
60
405
103
818
1.73
2.74
5.4
3.2
79.86
49.38
u/l
1.13
98
758
12
41
3.08
2.68
3.0
1.6
—
—
—
0
0
71
516
1.68
2.59
5.8
4.0
77.73
35.81
ng/l
0.95
54
386
48
316
1.74
2.50
1.5
1.3
2.50
2.16
u/ml
0.06
14
80
32
186
1.90
2.48
14.3
7.2
104.53
104.73
mmol/l
0.09
32
186
46
302
1.73
2.41
3.0
1.7
0.80
1.62
mg/l
1.97
36
235
11
39
2.95
2.39
3.2
1.6
—
—
—
0
0
5
8
6.41
2.39
1.2
1.3
—
—
—
0
0
36
222
1.80
2.32
5.0
3.2
0.75
1.97
e6/l
0.94
20
116
7
18
4.02
2.28
3.1
1.6
—
—
—
0
0
34
211
1.78
2.15
1.3
1.3
29.22
24.91
iu/ml
—
10
66
32
196
1.79
2.11
1.3
1.3
33.64
13.06
u/ml
—
9
80
9
31
3.01
2.11
1.9
1.3
—
—
—
0
0
5
10
5.12
2.08
1.0
1.3
111.20
62.12
ng/l
—
5
10
140
1252
1.95
2.08
42.8
15.5
22.17
24.70
mg/l
0.54
128
1033
56
401
1.61
2.08
5.4
3.3
0.08
0.33
e6/l
2.14
44
300
6
15
4.11
2.06
2.3
1.8
—
—
—
0
0
131
1154
1.75
1.97
6.1
5.3
2.06
1.97
mu/l
0.34
124
1038
6
16
3.85
1.95
2.7
3.6
6.12
3.11
nmol/l
—
6
16
6
16
3.85
1.95
2.0
1.6
—
—
—
0
0
92
751
1.53
1.87
3.4
3.1
—
—
—
0
0
6
17
3.62
1.85
2.3
1.7
—
—
—
0
0
5
12
4.26
1.83
1.4
1.2
—
—
—
0
0
5
12
4.26
1.83
1.6
1.8
—
—
—
0
0
5
12
4.26
1.83
1.6
1.8
—
—
—
0
0
5
12
4.26
1.83
1.6
1.8
—
—
—
0
0
9
35
2.66
1.83
1.0
1.3
—
—
—
0
0
59
441
1.54
1.78
4.5
3.4
2828.89
1427.76
ng/l
1.19
54
369
8
30
2.75
1.75
1.9
1.5
—
—
—
0
0
36
242
1.63
1.70
5.2
3.0
0.55
0.94
e6/l
0.75
21
134
10
40
2.60
1.70
1.9
1.1
—
—
—
0
0
7
25
2.88
1.67
1.0
1.2
—
—
—
0
0
5
14
3.65
1.63
1.6
1.3
—
—
—
0
0
5
14
3.65
1.63
1.2
1.2
—
—
—
0
0
7
26
2.77
1.60
3.7
1.6
—
—
—
0
0
6
20
3.08
1.59
1.0
1.1
—
—
—
0
0
6
21
2.93
1.52
1.0
1.0
—
—
—
0
0
10
45
2.30
1.49
1.4
1.3
—
—
—
0
0
23
142
1.72
1.48
6.7
2.9
—
—
—
0
0
7
28
2.57
1.47
1.3
1.3
—
—
—
0
0
55
421
1.47
1.44
6.4
4.2
13.75
8.92
mg/mmol
0.40
39
261
37
262
1.54
1.40
4.4
3.0
2.50
2.45
mmol/l
1.16
31
233
9
43
2.16
1.32
1.1
1.3
—
—
—
0
0
9
43
2.16
1.32
1.9
1.2
0.26
0.23
g/l
—
9
43
5
18
2.83
1.29
2.0
2.1
9.60
10.67
mmol/l
—
5
18
9
44
2.11
1.29
1.1
1.3
—
—
—
0
0
8
38
2.16
1.20
1.3
1.2
—
—
—
0
0
5
20
2.55
1.16
1.4
1.7
—
—
—
0
0
21
136
1.63
1.15
1.7
1.6
1.55
1.43
%
0.49
15
120
9
45
2.06
1.07
1.9
1.2
1.25
1.13
g/l
—
9
45
84
723
1.34
1.04
5.2
3.7
0.00
0.00
estimate
-0.00
23
152
10
54
1.91
0.99
6.9
3.2
2.28
1.41
mg/l
—
10
48
6
27
2.27
0.94
2.0
1.2
—
—
—
0
0
16
103
1.61
0.91
16.3
2.7
1.21
1.22
mmol/l
0.47
16
88
84
733
1.31
0.90
5.2
3.7
0.00
0.00
estimate
-0.00
23
154
84
736
1.30
0.86
5.4
3.7
0.00
0.00
estimate
-0.00
23
143
15
99
1.57
0.79
4.2
2.9
62.25
61.40
ml/min/173m2
—
8
35
5
25
2.03
0.73
1.8
1.9
4.90
5.44
u/ml
—
5
25
49
415
1.26
0.63
4.6
3.7
0.00
0.01
estimate
0.50
21
141
11
73
1.54
0.58
1.1
1.5
—
—
—
0
0
6
36
1.69
0.57
2.3
2.3
—
—
—
0
0
6
38
1.60
0.55
1.5
1.2
0.77
0.88
g/l
—
6
38
30
244
1.28
0.53
3.3
3.1
1.17
0.82
ug/l
0.30
20
165
20
253
0.76
0.49
1.8
1.6
—
—
—
0
0
47
410
1.21
0.46
4.7
3.1
0.00
0.00
estimate
-0.00
20
121
12
161
0.72
0.43
8.5
7.4
—
—
—
0
0
0
16
0.00
0.41
0.0
1.2
—
—
—
0
0
0
18
0.00
0.40
0.0
1.8
—
—
—
0
0
127
1217
1.21
0.40
6.2
5.7
2.44
2.60
mmol/l
1.10
119
1115
118
1125
1.19
0.38
4.7
4.2
1.41
1.23
mmol/l
1.46
108
1023
8
65
1.24
0.27
5.1
4.1
49.96
44.13
%
—
8
65
5
37
1.36
0.24
1.0
1.2
—
—
—
0
0
59
550
1.12
0.23
4.7
3.6
0.00
0.03
estimate
0.68
21
127
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
122
1186
1.12
0.21
6.6
5.2
5.95
5.91
mmol/l
0.11
113
1068
14
119
1.19
0.18
4.1
2.3
0.57
0.93
e6/l
0.19
14
113
7
60
1.17
0.18
1.4
1.6
1308.89
954.61
mu/l
—
7
49
122
1191
1.10
0.16
5.4
5.1
4.31
4.51
mmol/l
1.26
115
1093
8
70
1.15
0.16
3.3
2.6
1.45
1.14
%
—
8
70
121
1183
1.09
0.15
5.3
5.0
1.37
1.47
mmol/l
1.53
113
1080
9
106
0.84
0.13
1.1
1.3
—
—
—
0
0
17
187
0.90
0.10
1.6
1.5
—
—
—
0
0
32
309
1.04
0.04
5.3
3.9
1.02
1.02
kg/l
0.36
20
194
14
131
1.08
0.03
2.6
2.2
—
—
—
0
0
42
429
0.97
0.02
6.0
5.7
2.09
2.62
ug/l
0.40
32
378
34
333
1.03
0.01
3.6
4.9
24.73
22.64
%
0.22
16
180
14
146
0.95
0.00
2.6
2.4
—
—
—
0
0
8
84
0.95
0.00
1.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
6
0.00
-0.00
0.0
2.7
—
10.47
—
0
6
0
9
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
7
69
1.02
-0.00
2.3
2.2
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
8
87
0.92
-0.00
2.4
2.3
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.2
—
0.29
—
0
6
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
-0.00
0.0
2.7
—
4.65
—
0
6
0
8
0.00
-0.00
0.0
1.6
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint D3_ACQPUREREDCLLAPLASIA and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| D3_ACQPUREREDCLLAPLASIA | 2.385 [1.8, 3.16] | < 0.001 |
| Birth year | 0.998 [0.99, 1.01] | 0.612 |
During the follow-up period (1.1.1998 — 31.12.2019), 214 out of 643 females with D3_ACQPUREREDCLLAPLASIA died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| D3_ACQPUREREDCLLAPLASIA | 3.507 [2.19, 5.62] | < 0.001 |
| Birth year | 0.986 [0.98, 1.0] | 0.003 |
During the follow-up period (1.1.1998 — 31.12.2019), 220 out of 570 males with D3_ACQPUREREDCLLAPLASIA died.
Mortality risk
Mortality risk for people of age
years, who have D3_ACQPUREREDCLLAPLASIA.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.271% | 0.578% |
| 5 | 1.616% | 3.729% |
| 10 | 4.04% | 9.649% |
| 15 | 7.368% | 16.673% |
| 20 | 12.727% | 26.796% |
Relationships between endpoints
↥Index endpoint: D3_ACQPUREREDCLLAPLASIA – Acquired pure red cell aplasia [erythroblastopenia]
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data